WASHINGTON--(BUSINESS WIRE)--More than a decade after initially being developed in a San Francisco Bay Area garage, The MVRx System is set to debut on a global stage.
The MVRx System, an implantable device, is designed to treat mitral valve regurgitation associated with heart failure that affects more than five million people worldwide. It was created by a cardiovascular surgeon and a team of industry veterans back in 2002. Now – after more than ten years of research, development, pre-clinical and human trials – the company is unveiling its proprietary device to treat Functional Mitral Regurgitation (FMR).
The story of The MVRx System begins like many medical technology startups. A team of talented entrepreneurs with a great idea saw an opportunity to make a difference in the lives of very sick patients. “I believe treatment should be revolutionary, not evolutionary,” says co-founder Robert Chang. “We designed, built and tested this product from the ground up starting in our garages until we had the support we needed to expand.”
The company received funding to begin human trials until a series of circumstances (including the 2008 financial crisis) forced the team to shelve the product. Everything was put in storage. But Chang and the founding team didn’t stop thinking or talking about their technology. And doctors listened. In late 2013, the team, partnering with several leading interventional cardiologists, decided it was time to pick up where the original promising data left off, and initiated a new clinical trial.
Their findings will be presented this coming weekend in Washington, D.C. at Transcatheter Cardiovascular Therapeutics (TCT) 2014, the world’s largest educational meeting focusing on interventional cardiovascular medicine. A team of cardiologists treating patients with The MVRx System will offer supportive data from the latest clinical trial. Chang believes the MVRx implant - minimally invasive, adaptable and affordable - could revolutionize the treatment of mitral valve regurgitation.
“We truly believe that our technology is the safest and most efficacious way to improve the lives of heart failure patients suffering from mitral valve regurgitation,” says Chang. “Reaching this important milestone is a testament to the determination and perseverance of the team. We look forward to helping many more patients in the future.”